| 1 |
Tapper H, Karlsson A, Mörgelin M, et al. Secretion of heparin-binding protein from human neutrophils is determined by its localization in azurophilic granules and secretory vesicles[J]. Blood, 2002, 99(5): 1785-1793.
|
| 2 |
Gautam N, Olofsson AM, Herwald H, et al. Heparin-binding protein (HBP/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability[J]. Nat Med, 2001, 7(10): 1123-1127.
|
| 3 |
Herwald H, Cramer H, Mörgelin M, et al. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage[J]. Cell, 2004, 116 (3): 367-379.
|
| 4 |
Tydén J, Herwald H, Sjöberg F, et al. Increased plasma levels of Heparin-binding protein on admission to intensive care are associsted with respiratory and circulatory failure[J]. PLoS One, 2016, 11(3): e0152035.
|
| 5 |
Dankiewicz J, Linder A, Annborn M, et al. Heparin-binding protein: An early indicator of critical illness and predictor of outcome in cardiac arrest[J]. Resuscitation, 2013, 84(7): 935-939.
|
| 6 |
Kjolvmark C, Akesson P, Linder A. Elevated urine levels of heparin-binding protein in children with urinary tract infection[J]. Pediatr Nephrol, 2012, 27(8): 1301-1308.
|
| 7 |
Linder A, Akesson P, Brink M, et al. Heparin-binding protein: A diagnostic marker of acute bacterial meningitis[J]. Crit Care Med, 2011, 39(4): 812-817.
|
| 8 |
Hans T, Anna K, Matthias M, et al. secrection of heparin-binding protein from human neutrophils is determined by its localization in azurophilic granules and secretory vesicles[J]. Blood, 2002, 99(5): 1785-1793.
|
| 9 |
Shafer WM, Martin LE, Spitznagel JK. Cationic antimicrobial proteins isolated from human neutrophil granulocytes in the presence of diisopropyl fluorophosphate[J]. Infect Immun, 1984, 45(1): 29-35.
|
| 10 |
Linder A, Soehnlein O, Akesson P. Roles of heparin-binding protein in bacterial infection[J]. J Innate Immun, 2010, 2(5): 431-438.
|
| 11 |
Lee TD, Gonzalez ML, Kunlar P, et al. CAP37, a neutropjil-derived inflammatory mediator, augnents leukocyte adhesion to endothelial monolayers[J]. Microvasc Res, 2003, 66(1): 38-48.
|
| 12 |
Bellingan GJ. The pulmonary physician in critical care * 6: The pathogenesis of ALI/ARDS[J]. Thorax, 2002, 57(6): 540-546.
|
| 13 |
Lin Q, Shen J, Shen L, et al. Increased plasma levels of heparin-binding protein in patients with acute respiratory distress syndrome[J]. Crit Care, 2013, 17(4): R155.
|
| 14 |
Kaukonen KM, Linko R, Herwald H, et al. Heparin-binding protein (HBP) in critically ill patients with influenza A (H1N1) infection[J]. Clin Microbiol Infect, 2013, 19(12): 1122-1128.
|
| 15 |
Johansson J, Bratstrom O, Sjoberg E, et al. Heparin-binding protein (HBP): an early marker of respiratory failure after trauma?[J]. Acta Anaesthesiol Scand, 2013, 57(5): 580-586.
|
| 16 |
Kjolvmark C, Tschernij E, Oberg J, et al. Distinguishing asymptomatic bacteriuria from urinary tract infection in the elderly-the use of urine levels of heparin-binding protein and interleukin-6[J]. Diagn Microbiol Infect Dis, 2016, 85(2): 243-248.
|
| 17 |
Lertdumrongluk K, Thongmee T, Kerr SJ, et al. Diagnostic accuracy of urine heparin binding protein for pediatric acute pyelonephritis[J]. Eur J Pediatr, 2015, 174(1): 43-48.
|
| 18 |
Pahlman LI, Morgelin M, Eckert J, et al. Streptococcal M protein : a multipotent and powerful inducer of inflammation[J], J Immunol 2006, 177(2): 1221-1228.
|
| 19 |
Linder A, Johansson L, Thulin P, et al. Erysipelascaused by group A streptococcua activates the contract system and induces the release of heparin-binding protein[J]. J Invest Dermatol, 2010, 130(5): 1365-1372.
|
| 20 |
Lundqvist K, Herwald H, Sonesson A, et al. Heparin binding protein is increased in chronic leg ulcer fluid and released from granulocytes by secreted products of pseudomonas aeruginosa[J]. Thromb Haemost, 2004, 92(2): 281-287.
|
| 21 |
van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis[J]. N Engl J Med, 2004, 351(18): 1849-1859.
|
| 22 |
Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis inadults. Areview of 493 episodes[J]. N Engl J Med, 1993, 328(1): 21-28.
|
| 23 |
Linder A, Christensson B, Herwald H, et al. Heparin-binding protein: an early marker of circulatory failure in sepsis[J]. Clin Infect Dis, 2009, 49(7): 1044-1050.
|
| 24 |
Weber JR, Angstwurm K, Rosenkranz T, et al. Heparin inhibits leukocyte rolling in pial vessels and attenuates inflammatory changes in a rat model of experimental bacterial meningitis[J]. J Cereb Blood Flow Metab, 1997, 17(11): 1221-1229.
|
| 25 |
Tuomanen EI, Saukkonen K, Sande S, et al. Reduction of inflammation, tissue damage, and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies against adhesion-promoting receptors of leukocytes[J]. J Exp Med, 1989, 170(3): 959-969.
|
| 26 |
Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock[J]. Crit Care Med, 2006, 34(6): 1589-1596.
|
| 27 |
Di Gennaro A, Kenne E, wan M, et a1. Leukotriene B4-induced changes in vascula permeability are mediated by neutrophil release of heparan_binding protein (HBP/cAP37/azurocidin)[J]. FASEB J, 2009, 23(6): 1750-1757.
|
| 28 |
Beran O, Herwald H, Dzupovao, et al. Heparin-binding protein as a biomarker of circulatory failure during severe infections: a report of three cases[J]. Scand J Infect Dis, 2010, 42(8): 634-636.
|
| 29 |
Linder A, Arnold R, Boyd JH, et al. Heparin-Binding Protein Measurement Improves the Prediction of Severe Infection With Organ Dysfunction in the Emergency Department[J]. Crit Care Med, 2015, 43(11): 2378-2386.
|
| 30 |
Linder A, Akesson P, Inglammar M, et al. Elevated plasma levels of heparin-binding protein in intensive care unit patients with severe sepsis and septic shock[J]. Crit Care, 2012, 16: R90.
|
| 31 |
Soehnlein O, Oehmcke S, Ma X, et al. Neutrophil degranulation mediates severe lung damage trigered mediates severe lung damage triggered by streptocaccal M1 protein[J]. Eur Respir J, 2008, 32(2): 405-412.
|
| 32 |
Johansson J, Lindbom L, Herwald H. Neutrophil-derived heparin binding protein-a mediator of increased vascular permeability after burns?[J]. Burns, 2009, 35(8): 1185-1187.
|
| 33 |
Medeiros RB, Oliveira FOR, Calvet CM. Involvement of host cell heparan sulfate proteoglycan in Trypanosoma cruzi amastigote attachment and invasion[J]. Parasitology, 2011, 138(5): 593-601.
|
| 34 |
Love DC, Esko JD, Mosser DM, et al. A Heparin-binding Activity on Leishmania Amastigotes Which Mediates Adhesion to Cellular Proteoglycans[J]. J Cell Biol, 1993, 123(3): 759-766.
|
| 35 |
Mukhopadhyay NK, Shome K, Saha, AK, et al. Heparin binds to Leishmania donovani promastigotes and inhibits protein phosphorylation[J]. Biochem, 1989, 264(2): 517-525.
|
| 36 |
Snall J, Linner A, Uhlmann J, Siemens N, et al. Differential neutrophil responses to bacterial stimuli: Streptococcal strain are potent inducers of heparin-binding protein and resistin-release[J]. Sci Rep, 2016, 6: 21288.
|
| 37 |
Griffin MP, Gore DC, Zwischenberger JB, et al. Does heparin improve survival in experimental porcine gam-negative septic shock?[J]. Circ Shick, 1990, 31(3): 343-349.
|
| 38 |
Tanaka T, Tsujinaka T, Kambayashi J, et al. The effect of heparin on multiple organ failure and disseminated intravascular coagulation in a sepsis model[J]. Thromb Res, 1990, 60(4): 321-330.
|
| 39 |
Boldt J, Papsdorf M, Piper SN, et al. Continuous heparinization and circulating adhesion molecules in the critically ill[J]. Shock, 1999, 11(1): 13-18.
|
| 40 |
Meyer J, Cox CS, Herndon DN, et al. Heparin in experimental hyperdynamic sepsis[J]. Crat Care Med, 1993, 21(1): 84-89.
|
| 41 |
Pernerstorfer T, Hollenstein U, Hansen J, et al. Heparin blunts endotoxin-induced coagulation activation[J]. Circulation, 1999, 100(25): 2485-2490.
|
| 42 |
Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. Highdose antithrombin III in severe sepsis: a randomized controlled trial[J]. JAMA, 2001, 286(15): 1869-1878.
|
| 43 |
Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial[J]. JAMA, 2003, 290(2): 238-247.
|
| 44 |
Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis[J]. N Engl J Med, 2001, 344(10): 699-709.
|